Proactive Investors - Run By Investors For Investors

FDA committee doesn’t think GSK’s asthma drug can be used to treat COPD as well

Nucala has already been approved to treat asthma patients, but an FDA advisory committee isn't convinced there is enough data to back up GSk's belief that it can help COPD patients as well
man coughing
Advisory committees' recommendations aren't binding, but it would be unusual for the FDA to go against their findings

GlaxoSmithKline PLC (LON:GSK) has been dealt a major blow after a US Food and Drug Administration advisory committee failed to give its backing to the drugs giant’s chronic obstructive pulmonary disorder treatment.

The FTSE 100 group’s Nucala drug has already been approved as a treatment for asthma, but GSK thinks it could also work in patients experiencing a sudden worsening of COPD.

READ: GSK unveils £1.7bn cost-cutting programme as it switches tack on R&D

The committee disagreed though, with 16 of the 19 members voting not to support approval, with the same number agreeing that there was “not substantial evidence of the efficacy”. They did, however, agree that the drug was safe.

As the name suggests, the advisory committee shares its thoughts with FDA regulators, but their recommendations are not binding.

That said, it would be unusual for the FDA to go against the committee, especially when the outcome is so clear.

As part of its report, the committee suggested that GSK go away and get some more data to show which patient population would be more likely to benefit.

GSK still confident

“Having participated in today's advisory committee meeting and heard the recommendation we will continue to work with the FDA to address outstanding questions,” said GSK’s senior vice president of respiratory R&D, Dave Allen.

“We remain confident our data supports mepolizumab as a targeted treatment for patients continuing to experience COPD exacerbations guided by blood eosinophil count.”

It is a blow for Glaxo and its boss, Emma Walmsley, who made respiratory drugs one of the company’s three core therapeutic areas of focus when she took the job almost a year ago.

Nucala generated sales of £141mln in the three months to the end of June. If it was approved for use in COPD, sales could potentially surge, as the disease affects almost 400mln people around the world.

Shares were down 3.7% at 1,485p in late morning trading.

View full GSK profile View Profile

GlaxoSmithKline PLC Timeline

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use